Outlook Wealth Advisors LLC trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 11,170 shares of the company’s stock after selling 86 shares during the quarter. Outlook Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $1,445,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Johnson & Johnson by 0.7% during the second quarter. Vanguard Group Inc. now owns 225,158,988 shares of the company’s stock worth $31,360,143,000 after purchasing an additional 1,627,370 shares during the last quarter. Phocas Financial Corp. increased its position in Johnson & Johnson by 999,928.6% during the second quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock worth $174,342,000 after purchasing an additional 125,161,066 shares during the last quarter. Northern Trust Corp increased its position in Johnson & Johnson by 0.9% during the second quarter. Northern Trust Corp now owns 35,255,462 shares of the company’s stock worth $4,910,381,000 after purchasing an additional 313,073 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Johnson & Johnson by 11.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock worth $2,895,870,000 after purchasing an additional 2,204,757 shares during the last quarter. Finally, Morgan Stanley increased its position in Johnson & Johnson by 0.6% during the second quarter. Morgan Stanley now owns 19,995,067 shares of the company’s stock worth $2,784,913,000 after purchasing an additional 122,033 shares during the last quarter. 72.05% of the stock is currently owned by institutional investors and hedge funds.
Several research firms recently issued reports on JNJ. Raymond James cut their price objective on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating for the company in a research report on Monday, October 14th. Wells Fargo & Co cut their price objective on shares of Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research report on Wednesday. Goldman Sachs Group set a $169.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Finally, Zacks Investment Research upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 price objective for the company in a research report on Thursday. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $151.18.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, beating analysts’ consensus estimates of $2.00 by $0.12. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.54%. The business had revenue of $20.73 billion during the quarter, compared to analysts’ expectations of $20.14 billion. During the same period last year, the business earned $2.05 earnings per share. The business’s revenue for the quarter was up 1.9% on a year-over-year basis. As a group, sell-side analysts expect that Johnson & Johnson will post 8.65 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date is Monday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 46.45%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Technical Analysis of Stocks, How Can It Help
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.